Long-term outcome of paediatric anti-N-methyl-D-aspartate receptor encephalitis.
Journal
Developmental medicine and child neurology
ISSN: 1469-8749
Titre abrégé: Dev Med Child Neurol
Pays: England
ID NLM: 0006761
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
26
08
2022
received:
21
12
2021
accepted:
05
09
2022
medline:
4
4
2023
pubmed:
6
10
2022
entrez:
5
10
2022
Statut:
ppublish
Résumé
To study long-term clinical and cognitive outcomes of patients with anti-N-methyl-d-aspartate receptor encephalitis (NMDAR-E), an acute autoimmune neurological disease with severe acute presentations. In this French multicentre retrospective observational cohort study, patients no older than 18 years with a follow-up of at least 2 years were included. Data from clinical and cognitive assessments were collected. Eighty-one patients were included (57 females, 24 males; median age 10 years 7 months [range 1-18 years], median follow-up 40 months [range 25-53 months]). At last follow-up, 35 patients (45%) had cognitive impairment, 48 (70%) had academic difficulties, and 65 (92%) needed rehabilitation. Seventy-one patients (88%) had a modified Rankin Scale score of no more than 2. A higher number of symptoms at diagnosis was associated with cognitive impairment (p = 0.01), while an abnormal electroencephalogram at diagnosis increased the risk of academic difficulties (p = 0.03). Although most children with NMDAR-E seemed to recover from motor disabilities, more than 45% had cognitive and academic difficulties. The initial severity of symptoms seems to have an impact on cognition and academic performances. Forty-five per cent of patients had cognitive impairment at ≥2 years diagnosis of anti-N-methyl-d-aspartate receptor encephalitis (NMDAR-E). Seventy per cent of patients had academic difficulties at ≥2 years diagnosis of NMDAR-E. Ninety-two per cent of patients needed rehabilitative care at ≥2 years diagnosis of NMDAR-E. A high number of symptoms at diagnosis were associated with cognitive impairment.
Substances chimiques
Receptors, N-Methyl-D-Aspartate
0
Types de publication
Observational Study
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
691-700Subventions
Organisme : Hospices Civils de Lyon
ID : NFS96-900
Informations de copyright
© 2022 Mac Keith Press.
Références
Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10(1):63-74.
Dalmau J, Tüzün E, Wu H, Masjuan J, Rossi JE, Voloschin A, et al. Paraneoplastic Anti-N-methyl-D-aspartate Receptor Encephalitis Associated with Ovarian Teratoma. Ann Neurol. 2007;61(1):25-36.
Armangue T, Titulaer MJ, Málaga I, Bataller L, Gabilondo I, Graus F, et al. Pediatric anti-N-methyl-D-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients. J Pediatr. 2013;162(4):850-856.e2.
Gresa-Arribas N, Titulaer MJ, Torrents A, Aguilar E, McCracken L, Leypoldt F, et al. Diagnosis and significance of antibody titers in anti-NMDA receptor encephalitis, a retrospective study. Lancet Neurol. 2014;13(2):167-77.
Lamarque M, Psimaras D, Ducray F, Pelieu I, Sonneville R, Demeret S, et al. Encéphalites auto-immunes à anticorps antirécepteurs-NMDA, une cause fréquente d'encéphalite en réanimation. Réanimation. 2011;20(5):397-407.
Jeannin-Mayer S, André-Obadia N, Rosenberg S, Boutet C, Honnorat J, Antoine JC, et al. EEG analysis in anti-NMDA receptor encephalitis: Description of typical patterns. Clin Neurophysiol. 2019;130(2):289-96.
Liu X, Yan B, Wang R, Li C, Chen C, Zhou D, et al. Seizure outcomes in patients with anti-NMDAR encephalitis: A follow-up study. Epilepsia. 2017;58(12):2104-11.
Moreton FC, Santosh C, McArthur K, Muir KW. Cerebral hyperperfusion on arterial spin labeling MRI during CADASIL migrainous encephalopathy. Neurology. 2015;85(24):2177-9.
Sachs JR, Zapadka ME, Popli GS, Burdette JH. Arterial spin labeling perfusion imaging demonstrates cerebral hyperperfusion in anti-NMDAR encephalitis. Radiol Case Rep. 2017;12(4):833-7.
Tobin WO, Strand EA, Clark HM, Lowe VJ, Robertson CE, Pittock SJ. NMDA receptor encephalitis causing reversible caudate changes on MRI and PET imaging. Neurol Clin Pract. 2014;4(6):470-3.
Schmitt SE, Pargeon K, Frechette ES, Hirsch LJ, Dalmau J, Friedman D. Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology. 2012;79(11):1094-100.
Tatencloux S, Chretien P, Rogemond V, Honnorat J, Tardieu M, Deiva K. Intrathecal treatment of anti-N-Methyl-D-aspartate receptor encephalitis in children. Dev Med Child Neurol. 2015;57(1):95-9.
Wang BJ, Wang CJ, Zeng ZL, Yang Y, Guo SG. Lower dosages of rituximab used successfully in the treatment of anti-NMDA receptor encephalitis without tumour. J Neurol Sci. 2017;377:127-32.
Yang XZ, Zhu HD, Ren HT, Zhu YC, Peng B, Cui LY, et al. Utility and Safety of Intrathecal Methotrexate Treatment in Severe Anti-N-methyl-D-aspartate Receptor Encephalitis: A Pilot Study. Chin Med J (Engl). 2018;131(2):156-60.
Zekeridou A, Karantoni E, Viaccoz A, Ducray F, Gitiaux C, Villega F, et al. Treatment and outcome of children and adolescents with N-methyl-D-aspartate receptor encephalitis. J Neurol. 2015;262(8):1859-66.
Wang H. Efficacies of treatments for anti-NMDA receptor encephalitis. Front Biosci Landmark Ed. 2016;21:651-63.
Nosadini M, Thomas T, Eyre M, Anlar B, Armangue T, Benseler SM, et al. International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis. Neurol Neuroimmunol Neuroinflammation. 2021;8(5):e1052.
Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis: A Meta-analysis | Adolescent Medicine | JAMA Neurology | JAMA Network [Internet]. 2022 [cited 3 May 2022]. Available from: https://jamanetwork.com/journals/jamaneurology/fullarticle/2784410
de Bruijn MAAM, Aarsen FK, van Oosterhout MP, van der Knoop MM, Catsman-Berrevoets CE, Schreurs MWJ, et al. Long-term neuropsychological outcome following pediatric anti-NMDAR encephalitis. Neurology. 2018;90(22):e1997-2005.
Iadisernia E, Battaglia FM, Vanadia E, Trapolino E, Vincent A, Biancheri R. Anti-N-methyl-D-aspartate-receptor encephalitis: cognitive profile in two children. Eur J Paediatr Neurol . 2012;16(1):79-82.
Favier M, Joubert B, Picard G, Rogemond V, Thomas L, Rheims S, et al. Initial clinical presentation of young children with N-methyl-d-aspartate receptor encephalitis. Eur J Paediatr Neurol . 2018;22(3):404-11.
Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study. Lancet Neurol. 2013;12(2):157-65.
Berrett TB, Samworth RJ. USP: an independence test that improves on Pearson's chi-squared and the G-test. Proc R Soc Math Phys Eng Sci. 2021;477(2256):20210549.
Bost C, Chanson E, Picard G, Meyronet D, Mayeur ME, Ducray F, et al. Malignant tumors in autoimmune encephalitis with anti-NMDA receptor antibodies. J Neurol. 2018;265(10):2190-200.
Chefdeville A, Treilleux I, Mayeur ME, Couillault C, Picard G, Bost C, et al. Immunopathological characterization of ovarian teratomas associated with anti-N-methyl-D-aspartate receptor encephalitis. Acta Neuropathol Commun. 2019;7(1):38.
Sidhom Y, Maillart E, Tezenas du Montcel S, Kacem I, Lubetzki C, Gouider R, et al. Fast multiple sclerosis progression in North Africans: Both genetics and environment matter. Neurology. 2017;88(13):1218-25.
Debouverie M, Lebrun C, Jeannin S, Pittion-Vouyovitch S, Roederer T, Vespignani H. More severe disability of North Africans vs Europeans with multiple sclerosis in France. Neurology. 2007;68(1):29-32.
Kim SH, Mealy MA, Levy M, Schmidt F, Ruprecht K, Paul F, et al. Racial differences in neuromyelitis optica spectrum disorder. Neurology. 2018;91(22):e2089-99.
Wright S, Hacohen Y, Jacobson L, Agrawal S, Gupta R, Philip S, et al. N-methyl-D-aspartate receptor antibody-mediated neurological disease: results of a UK-based surveillance study in children. Arch Dis Child. 2015;100(6):521-6.
Hallowell S, Tebedge E, Oates M, Hand E. Rituximab for Treatment of Refractory Anti-NMDA Receptor Encephalitis in a Pediatric Patient. J Pediatr Pharmacol Ther . 2017;22(2):118-23.